Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
09.09.2026 11:29
NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For AllPreviously published by the Robert A. Winn Excellence in Clinical Trials Award ProgramA growing coalition of pharmaceutical companies, nonprofit organizations, academic institutions, and clinical research leaders came together through the Robert A.
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
09.09.2026 11:00
PHILADELPHIA & BOSTON, September 09, 2026--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medi
SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
09.09.2026 09:50
Potential extends to earlier-line use, injection-averse patients and new immune-mediated indicationsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "SOTYKTU Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France,
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
06.09.2026 10:44
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup
05.09.2026 10:33
BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.
Sector Update: Healthcare Stocks Decline Late Afternoon
04.09.2026 19:48
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Sector Update: Healthcare Stocks Decline Friday Afternoon
04.09.2026 17:41
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
04.09.2026 11:33
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
04.09.2026 10:10
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
04.09.2026 09:35
Bristol Myers Squibb (BMY) stock: Strong Buy at 51% sector discount.
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
04.09.2026 07:15
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
03.09.2026 14:00
Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
03.09.2026 11:30
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicin
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
03.09.2026 05:51
Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.
What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?
03.09.2026 04:31
Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
02.09.2026 13:00
Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...
Reported Earlier, Bristol Myers Reports Long-Term Camzyos Data Supporting Continued Use In Obstructive HCM
31.08.2026 03:40
Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in
Adicet Bio: A Cheap Gamma Delta T-Cell Play
14.08.2026 13:18
Adicet Bio trades below cash ahead of a pivotal 3Q 2026 lupus nephritis CAR-T readout. Click here to read more about the ACET stock.
Bristol Myers Squibb to build $2.3 billion Houston campus
10.08.2026 17:37
The roughly 600,000-square-foot facility at Generation Park will create nearly 500 permanent jobs and about 2,000 construction positions
Major pharmaceutical company plans $2.3B Houston manufacturing campus, 500 jobs
10.08.2026 16:27
A major pharmaceutical company plans to invest approximately $2.3 billion in a new manufacturing campus in Houston, a project expected to create nearly 500 jobs. Gov. Greg Abbott announced Monday that Bristol Myers Squibb will establish the new pharmaceutical manufacturing campus at Generation Park in Harris County. The New Jersey-based global biopharmaceutical company focuses on discovering, developing and delivering medicines for serious diseases.